Although lung adenocarcinomas (LADs) with ground-glass opacity (GGO; part-solid tumors) have been shown to differ from those without GGO (pure-solid tumors) in clinicopathological features and prognoses, whether programmed death ligand-1 (PD-L1) protein expression differs between these two tumor types is unclear. This study included 124 patients with clinical T1a-c LAD who received pulmonary resections during 2007-2009. The E1L3N antibody was used to stain for PD-L1 in primary LAD specimens. The specimens were considered PD-L1 if ≥1% of tumor cells showed membrane staining, and were classified as having a high PD-L1 tumor proportion score (TPS) if ≥50% of the tumor cells did so. Among the 124 patients, 45 had part-solid tumors and 79 had pure-solid tumors. These two groups did not significantly differ in terms of clinical factors. However, the rates for PD-L1 positivity (4% vs. 25%, < 0.01) and high PD-L1 TPS (2% vs. 16%, = 0.02) were significantly higher in the pure-solid tumors. The multivariate analyses (logistic regression model) showed that the odds ratios for PD-L1 positivity and high PD-L1 TPS in pure-solid LADs were 5.9 (95% CI; 1.2-29.7) and 8.0 (95% CI; 1.0-63.8), respectively. In conclusion, LADs with GGO were correlated with a lower incidence of PD-L1 expression than pure-solid tumors.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769535 | PMC |
http://dx.doi.org/10.3390/biom9090456 | DOI Listing |
Hum Pathol
January 2025
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, 30322, USA. Electronic address:
Introduction: Extraskeletal myxoid chondrosarcoma (EMC) is a rare sarcoma defined by NR4A3 gene rearrangements, typically featuring uniform cells with eosinophilic cytoplasm and mild atypia, arranged in cords or clusters within a chondromyxoid stroma. A cellular variant, characterized by increased cellular density and a solid growth pattern, has been recognized.
Methods: We encountered three cases of round cell sarcomas, diagnosed as EMC based on NR4A3 or NR4A2 rearrangements.
Gen Thorac Cardiovasc Surg
January 2025
Department of General Thoracic Surgery, Juntendo University School of Medicine, 1-3 Hongo 3-chome, Bunkyo-ku, Tokyo, 113-8421, Japan.
Acad Radiol
January 2025
Department of Nuclear Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Key Laboratory of Novel Nuclide Technologies on Precision Diagnosis and Treatment & Clinical Transformation of Wenzhou City, China (K.T.). Electronic address:
Asian J Surg
November 2024
Department of Thoracic Surgery, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Electronic address:
Background: The outcomes of segmentectomy for small (≤2 cm) non-small cell lung cancer (NSCLC) have been well demonstrated. This study aimed to investigate whether segmentectomy could achieve comparable oncologic outcomes with lobectomy for >2-3 cm lung cancer.
Methods: Patients who underwent segmentectomy or lobectomy for NSCLC >2-3 cm were retrospectively screened.
J Thorac Oncol
October 2024
JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!